Reggie E. Duerst, MD

Director, Stem Cell Transplant Program

Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Language: English

Appointments & Referrals

1.800.543.7362 (1.800.KIDS DOC)

About Me

Clinical Interests: Stem cell transplantation; cancer survivorship; stem cell transplantation outcomes research

Specialties, Programs & Conditions

Specialties:

Programs & Conditions:

Stem Cell Transplantation Program

Education & Training

Education: University of Wisconsin, Madison, 1979

Postgraduate Training: University of Rochester School of Medicine & Dentistry, 1987; University of Minnesota Health Sciences Center, 1986; Strong Memorial Hospital, 1982

Board Certifications: Pediatric Hematology-Oncology, General Pediatrics

See Northwestern University Faculty Profile >

Research

Northwestern Scholars Profile >

Publications

Most recent publications

High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes Pediatr Hematol Oncol1-6
Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease Hematol Oncol Stem Cell Ther11 (3): 169-174
Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant Pediatr Blood Cancer64 (9):
The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients J Pediatr Hematol Oncol39 (1): 26-32
IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients Bone Marrow Transplant51 (10): 1394-1396
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure Blood127 (13): 1656-65
Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy Leuk Lymphoma57 (4): 949-52
Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation Biol Blood Marrow Transplant21 (9): 1612-21
Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease Pediatr Transplant15 (3): 334-43
Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation Biol Blood Marrow Transplant16 (3): 350-7

See All